Index S&P 500 P/E 74.96 EPS (ttm) 1.04 Insider Own 1.06% Shs Outstand 158.22M Perf Week 4.86%
Market Cap 12.42B Forward P/E 36.09 EPS next Y 2.17 Insider Trans -1.18% Shs Float 156.97M Perf Month 7.78%
Income 168.08M PEG 6.66 EPS next Q 0.38 Inst Own 99.39% Short Float 2.08% Perf Quarter 6.30%
Sales 1.16B P/S 10.72 EPS this Y 4.54% Inst Trans 1.96% Short Ratio 3.32 Perf Half Y 8.25%
Book/sh 13.08 P/B 5.99 EPS next Y 17.25% ROA 6.06% Short Interest 3.27M Perf Year 10.48%
Cash/sh 0.96 P/C 81.27 EPS next 5Y 11.25% ROE 8.33% 52W Range 51.79 - 85.57 Perf YTD 1.48%
Dividend Est. 0.25 (0.33%) P/FCF 52.61 EPS past 5Y 11.13% ROI 6.79% 52W High -8.50% Beta 1.27
Dividend TTM 0.32 (0.41%) Quick Ratio 2.75 Sales past 5Y 10.61% Gross Margin 66.70% 52W Low 51.19% ATR (14) 2.45
Dividend Ex-Date Aug 19, 2024 Current Ratio 3.87 EPS Y/Y TTM -41.27% Oper. Margin 21.42% RSI (14) 60.75 Volatility 3.39% 3.02%
Employees 3100 Debt/Eq 0.20 Sales Y/Y TTM 1.97% Profit Margin 14.50% Recom 1.62 Target Price 83.17
Option/Short Yes / Yes LT Debt/Eq 0.20 EPS Q/Q -45.81% Payout 30.61% Rel Volume 1.58 Prev Close 80.36
Sales Surprise -0.13% EPS Surprise -0.99% Sales Q/Q 1.59% Earnings Aug 07 BMO Avg Volume 985.53K Price 78.30
SMA20 6.75% SMA50 4.02% SMA200 6.84% Trades
Volume 1,558,280 Change -2.56%
Date
Action
Analyst
Rating Change
Price Target Change
May-22-24 Downgrade Citigroup
Buy → Neutral
$85
Feb-08-24 Initiated Scotiabank
Sector Outperform
$80
Feb-02-24 Downgrade Stifel
Buy → Hold
$65
Dec-07-23 Initiated UBS
Buy
$80
Aug-28-23 Initiated William Blair
Outperform
Jan-10-23 Upgrade Wells Fargo
Underweight → Equal Weight
$90
Dec-14-22 Initiated Deutsche Bank
Buy
$100
Dec-12-22 Upgrade Citigroup
Neutral → Buy
$81.25 → $100
Dec-07-22 Initiated RBC Capital Mkts
Sector Perform
$89
Aug-25-22 Initiated Credit Suisse
Outperform
$465
Apr-25-22 Downgrade Wells Fargo
Equal Weight → Underweight
$370
Sep-15-21 Upgrade KeyBanc Capital Markets
Sector Weight → Overweight
$600
Mar-08-21 Upgrade Stephens
Equal-Weight → Overweight
$380 → $425
Feb-23-21 Upgrade Stifel
Hold → Buy
$435
Jan-25-21 Reiterated The Benchmark Company
Buy
$320 → $410
Nov-10-20 Initiated KeyBanc Capital Markets
Sector Weight
$340
Sep-30-20 Initiated Atlantic Equities
Overweight
$365
Jul-15-20 Downgrade Stephens
Overweight → Equal-Weight
May-27-20 Downgrade Stifel
Buy → Hold
$245 → $260
May-14-20 Initiated The Benchmark Company
Buy
$290
Show Previous Ratings
Sep-19-24 06:37PM
(Morningstar Research) +5.03%
Sep-18-24 07:00AM
07:00AM
Sep-17-24 07:00AM
07:00AM
07:00AM
Loading…
Sep-16-24 07:00AM
Sep-09-24 05:11AM
Aug-27-24 07:00AM
Aug-26-24 07:00AM
Aug-23-24 01:04AM
Aug-08-24 02:28PM
Aug-07-24 07:20PM
(Morningstar Research) -9.51%
06:30AM
06:30AM
Jul-31-24 07:00AM
07:00AM
Loading…
Jul-29-24 07:00AM
Jul-15-24 07:00AM
Jul-12-24 06:58PM
Jul-09-24 06:00AM
Jul-02-24 07:06PM
May-31-24 07:00AM
May-30-24 07:00AM
May-29-24 07:00AM
May-23-24 10:26AM
07:00AM
May-22-24 07:00AM
May-20-24 01:34PM
May-14-24 04:49AM
May-08-24 07:00AM
May-07-24 07:00AM
05:57AM
Loading…
May-06-24 05:57AM
May-02-24 11:40AM
11:31AM
10:49AM
10:34AM
08:17AM
08:00AM
03:11AM
May-01-24 04:54PM
02:05PM
01:52PM
12:08PM
11:10AM
09:30AM
08:36AM
07:51AM
07:40AM
07:29AM
06:30AM
06:30AM
Apr-30-24 07:00AM
Apr-29-24 10:38AM
09:39AM
07:00AM
Apr-26-24 07:00AM
Apr-24-24 10:01AM
Apr-23-24 07:00AM
Apr-10-24 07:00AM
Apr-08-24 07:00AM
Apr-03-24 07:00AM
Apr-01-24 07:00AM
Mar-28-24 09:00AM
08:39AM
Mar-22-24 07:00AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-12-24 07:00AM
Mar-11-24 07:00PM
Mar-06-24 07:00AM
Feb-23-24 06:15AM
Feb-13-24 08:00AM
Feb-02-24 10:47AM
04:45AM
(Thomson Reuters StreetEvents)
Feb-01-24 12:57PM
07:51AM
07:07AM
06:30AM
06:30AM
Jan-29-24 07:00AM
Jan-25-24 07:00AM
Jan-24-24 07:00AM
Jan-21-24 01:16PM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
Jan-04-24 07:00AM
Dec-21-23 07:00AM
Dec-20-23 07:00AM
Dec-14-23 07:00AM
Dec-01-23 01:32AM
Nov-27-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 07:00AM
Nov-01-23 10:44AM
Oct-31-23 07:53AM
07:27AM
06:30AM
06:30AM
Oct-25-23 03:42PM
09:00AM
Oct-22-23 10:30AM
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HIGGINS JOHN L Director Sep 12 '24 Option Exercise 22.95 6,000 137,700 48,608 Sep 16 04:18 PM Kelderman Kim Chief Executive Officer Aug 29 '24 Option Exercise 66.97 1,492 99,919 41,434 Sep 03 04:05 PM Bohnen Shane SVP - General Counsel Aug 15 '24 Option Exercise 0.00 49 0 1,696 Aug 19 05:28 PM BAUMGARTNER ROBERT V Director Aug 08 '24 Option Exercise 22.95 16,000 367,200 59,401 Aug 12 04:08 PM BAUMGARTNER ROBERT V Director Aug 08 '24 Sale 72.10 16,000 1,153,664 43,401 Aug 12 04:08 PM ROBERT V. BAUMGARTNER Director Aug 08 '24 Proposed Sale 72.10 16,000 1,153,664 Aug 08 04:13 PM Hippel James CFO Aug 02 '24 Option Exercise 31.26 53,000 1,656,780 136,002 Aug 06 04:23 PM Kelderman Kim Chief Executive Officer Jul 31 '24 Option Exercise 37.70 14,000 527,800 49,421 Aug 02 04:17 PM Hippel James CFO Jul 23 '24 Option Exercise 31.26 35,000 1,094,100 107,284 Jul 25 04:31 PM HIGGINS JOHN L Director Jul 08 '24 Option Exercise 22.95 6,000 137,700 42,608 Jul 10 04:35 PM HIGGINS JOHN L Director May 14 '24 Option Exercise 22.95 4,000 91,800 40,608 May 16 04:17 PM HIGGINS JOHN L Director May 14 '24 Sale 83.84 4,000 335,377 36,608 May 16 04:17 PM Nusse Roeland Director Mar 07 '24 Sale 76.98 10,400 800,627 43,097 Mar 11 04:04 PM Hippel James CFO Dec 19 '23 Option Exercise 31.26 47,289 1,478,254 104,850 Dec 21 04:06 PM
Index RUT P/E - EPS (ttm) -0.62 Insider Own 19.43% Shs Outstand 116.86M Perf Week -2.00%
Market Cap 517.71M Forward P/E - EPS next Y -0.40 Insider Trans 1.97% Shs Float 94.37M Perf Month 6.00%
Income -62.38M PEG - EPS next Q -0.14 Inst Own 55.02% Short Float 8.21% Perf Quarter 10.78%
Sales 21.71M P/S 23.85 EPS this Y -12.25% Inst Trans 0.72% Short Ratio 12.95 Perf Half Y -14.01%
Book/sh 2.49 P/B 1.78 EPS next Y 29.88% ROA -16.80% Short Interest 7.74M Perf Year -12.82%
Cash/sh 0.49 P/C 9.05 EPS next 5Y - ROE -19.87% 52W Range 3.56 - 6.72 Perf YTD -28.36%
Dividend Est. - P/FCF - EPS past 5Y - ROI -19.81% 52W High -34.18% Beta -0.09
Dividend TTM - Quick Ratio 4.75 Sales past 5Y 13.92% Gross Margin 4.08% 52W Low 24.16% ATR (14) 0.18
Dividend Ex-Date - Current Ratio 4.75 EPS Y/Y TTM -179.08% Oper. Margin -381.54% RSI (14) 52.31 Volatility 3.89% 3.84%
Employees 106 Debt/Eq 0.08 Sales Y/Y TTM -63.33% Profit Margin -287.29% Recom 1.00 Target Price 10.00
Option/Short Yes / Yes LT Debt/Eq 0.07 EPS Q/Q 9.19% Payout - Rel Volume 1.57 Prev Close 4.73
Sales Surprise 31.95% EPS Surprise 24.11% Sales Q/Q 9.62% Earnings Aug 08 AMC Avg Volume 597.91K Price 4.42
SMA20 2.55% SMA50 0.49% SMA200 -10.64% Trades
Volume 935,958 Change -6.55%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-29-23 Initiated RBC Capital Mkts
Outperform
$6
Apr-21-23 Initiated The Benchmark Company
Buy
$8
Apr-13-23 Initiated Craig Hallum
Buy
$10
Feb-22-23 Initiated Cowen
Outperform
$10
Feb-13-23 Initiated H.C. Wainwright
Buy
$11
Dec-20-22 Initiated Truist
Buy
$10
Dec-16-22 Initiated Credit Suisse
Outperform
$13
Nov-29-22 Initiated SVB Leerink
Outperform
$6
Nov-28-22 Initiated Stifel
Buy
$12
Aug-26-24 08:00AM
Aug-08-24 04:05PM
Jul-25-24 08:00AM
Jun-03-24 04:05PM
May-20-24 08:05AM
04:05PM
Loading…
May-15-24 04:05PM
May-12-24 03:24PM
May-09-24 08:56PM
04:05PM
May-01-24 08:00AM
Apr-22-24 08:00AM
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
08:00AM
Loading…
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
08:06AM
Loading…
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
(Thomson Reuters StreetEvents)
+8.36%
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
Mar-31-23 08:40AM
Mar-30-23 04:05PM
Mar-15-23 11:44AM
Mar-09-23 08:00AM
Mar-08-23 09:53AM
Feb-23-23 07:49AM
Feb-07-23 08:00AM
Feb-01-23 06:56AM
Dec-16-22 12:39PM
Dec-01-22 08:47AM
Nov-15-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 07:00AM
Nov-01-22 04:01PM
04:01PM
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Avista Capital Managing Member 10% Owner Jun 29 '24 Option Exercise 3.35 66,668 223,338 15,992,372 Jul 02 05:00 PM FOEHR MATTHEW W President and CEO Jun 27 '24 Option Exercise 3.73 59,659 222,416 3,599,166 Jun 27 04:55 PM FOEHR MATTHEW W President and CEO May 24 '24 Buy 4.42 240,000 1,059,840 3,536,665 May 28 05:55 PM GUSTAFSON KURT A Executive VP, Finance and CFO Apr 08 '24 Sale 5.27 6,954 36,648 176,697 Apr 09 06:38 PM Berkman Charles S Chief Legal Officer Apr 08 '24 Sale 5.27 6,954 36,648 292,617 Apr 09 06:37 PM GUSTAFSON KURT A Executive VP, Finance & CFO Apr 01 '24 Sale 5.46 11,849 64,696 170,110 Apr 02 06:30 PM FOEHR MATTHEW W President and CEO Mar 27 '24 Option Exercise 3.72 243,613 907,023 3,152,416 Mar 29 04:52 PM FOEHR MATTHEW W President and CEO Mar 22 '24 Buy 5.19 225,000 1,167,750 2,908,803 Mar 25 07:07 AM FOEHR MATTHEW W Chief Executive Officer Dec 12 '23 Buy 5.05 200,000 1,010,000 2,645,442 Dec 13 03:25 PM FOEHR MATTHEW W President and CEO Nov 10 '23 Buy 4.27 95,000 405,517 2,427,919 Nov 13 08:00 AM
Index RUT P/E 44.47 EPS (ttm) 2.31 Insider Own 2.35% Shs Outstand 18.27M Perf Week -1.88%
Market Cap 1.88B Forward P/E 16.45 EPS next Y 6.25 Insider Trans -15.36% Shs Float 17.84M Perf Month -3.09%
Income 42.14M PEG 2.22 EPS next Q 1.34 Inst Own 96.12% Short Float 5.58% Perf Quarter 29.49%
Sales 133.48M P/S 14.07 EPS this Y -11.43% Inst Trans -0.31% Short Ratio 8.17 Perf Half Y 40.90%
Book/sh 42.82 P/B 2.40 EPS next Y 15.82% ROA 5.19% Short Interest 1.00M Perf Year 68.36%
Cash/sh 12.42 P/C 8.28 EPS next 5Y 20.00% ROE 5.85% 52W Range 49.24 - 112.12 Perf YTD 43.94%
Dividend Est. - P/FCF 41.47 EPS past 5Y -13.18% ROI 5.39% 52W High -8.32% Beta 1.03
Dividend TTM - Quick Ratio 15.70 Sales past 5Y -3.89% Gross Margin 67.15% 52W Low 108.77% ATR (14) 3.23
Dividend Ex-Date Jul 02, 2010 Current Ratio 16.82 EPS Y/Y TTM 53.74% Oper. Margin 5.98% RSI (14) 49.49 Volatility 2.24% 2.96%
Employees 58 Debt/Eq 0.01 Sales Y/Y TTM -28.55% Profit Margin 31.57% Recom 1.17 Target Price 124.00
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q -2328.72% Payout 0.00% Rel Volume 3.16 Prev Close 105.01
Sales Surprise 25.71% EPS Surprise 32.55% Sales Q/Q 57.52% Earnings Aug 06 AMC Avg Volume 121.76K Price 102.80
SMA20 -1.05% SMA50 0.13% SMA200 24.42% Trades
Volume 384,755 Change -2.10%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-30-24 Initiated RBC Capital Mkts
Outperform
$130
Apr-14-21 Resumed Stephens
Overweight
$200
Feb-04-21 Reiterated H.C. Wainwright
Buy
$229 → $310
Oct-06-20 Initiated Barclays
Overweight
$156
Mar-24-20 Downgrade Argus
Buy → Hold
Mar-10-20 Initiated Guggenheim
Neutral
Feb-06-20 Initiated The Benchmark Company
Buy
$135
Sep-19-19 Upgrade Barclays
Equal Weight → Overweight
$110 → $132
Jun-11-19 Initiated Barclays
Equal Weight
$131
May-03-19 Reiterated H.C. Wainwright
Buy
$254 → $214
Mar-06-19 Reiterated H.C. Wainwright
Buy
$281 → $254
Oct-29-18 Upgrade ROTH Capital
Neutral → Buy
Oct-02-18 Reiterated H.C. Wainwright
Buy
$270 → $280
Sep-11-18 Reiterated Argus
Buy
$260 → $300
Aug-17-18 Initiated Goldman
Neutral
$256
Aug-08-18 Downgrade ROTH Capital
Buy → Neutral
Jun-21-18 Initiated Argus
Buy
$260
Dec-27-17 Reiterated H.C. Wainwright
Buy
$163 → $169
Sep-05-17 Resumed H.C. Wainwright
Buy
$150
Oct-05-16 Reiterated H.C. Wainwright
Buy
$146 → $160
Show Previous Ratings
Sep-06-24 09:20AM
Aug-20-24 09:00AM
Aug-06-24 04:01PM
Jul-24-24 06:30AM
Jul-23-24 04:01PM
07:00AM
Loading…
Jul-08-24 07:00AM
Jul-01-24 08:00AM
Jun-27-24 08:00AM
Jun-18-24 08:00AM
Jun-14-24 12:00PM
Jun-06-24 11:31AM
Jun-04-24 09:55AM
08:50AM
May-23-24 04:59PM
May-20-24 06:00AM
12:00PM
Loading…
May-13-24 12:00PM
May-10-24 08:50AM
May-09-24 09:40AM
May-08-24 01:22PM
12:19PM
May-07-24 09:01PM
05:40PM
04:00PM
11:29AM
07:30AM
Apr-23-24 08:31AM
Apr-17-24 09:55AM
Apr-08-24 08:15AM
Apr-05-24 06:00PM
Apr-04-24 09:30AM
09:00AM
Loading…
09:00AM
Apr-03-24 09:00AM
Apr-01-24 06:15PM
Mar-28-24 11:30AM
Mar-26-24 06:15PM
Mar-21-24 09:00AM
Mar-20-24 06:00PM
Mar-19-24 09:30AM
Mar-14-24 06:00PM
Mar-07-24 09:00AM
Mar-05-24 04:01PM
Mar-04-24 08:00AM
Feb-29-24 09:30AM
Feb-28-24 07:34AM
Feb-27-24 07:00AM
Feb-22-24 04:01PM
Feb-16-24 08:00AM
Feb-13-24 04:01PM
Feb-01-24 05:00PM
Jan-10-24 07:30PM
Jan-05-24 04:30PM
Dec-12-23 12:01PM
09:00AM
09:00AM
Dec-11-23 09:00AM
Dec-06-23 04:02PM
Dec-01-23 08:20AM
Nov-28-23 09:01AM
Nov-09-23 04:47PM
Nov-08-23 04:01PM
Nov-06-23 09:00AM
Nov-01-23 08:00AM
Oct-25-23 04:01PM
Oct-18-23 08:00AM
Oct-09-23 06:15PM
Oct-03-23 06:00PM
Oct-02-23 09:00AM
09:00AM
Sep-27-23 09:00AM
Sep-26-23 05:05PM
Sep-22-23 09:00AM
Sep-21-23 09:20AM
Sep-18-23 05:17PM
Sep-01-23 10:02PM
Aug-08-23 04:01PM
Jul-27-23 01:30PM
Jul-25-23 04:30PM
Jul-17-23 08:59AM
08:45AM
Jun-29-23 09:00AM
Jun-21-23 08:00PM
Jun-09-23 09:40AM
Jun-06-23 11:40AM
11:10AM
Jun-05-23 11:49AM
09:01AM
Jun-02-23 12:39PM
12:35PM
Jun-01-23 11:29AM
May-30-23 07:01PM
May-25-23 05:00PM
May-24-23 09:55AM
09:40AM
May-17-23 01:59PM
08:07AM
May-16-23 09:56AM
07:30AM
07:00AM
May-12-23 12:08PM
11:34AM
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Korenberg Matthew E Officer Sep 20 '24 Proposed Sale 104.10 6,275 653,238 Sep 20 06:12 PM Espinoza Octavio Officer Sep 20 '24 Proposed Sale 103.94 1,275 132,518 Sep 20 05:39 PM Espinoza Octavio Chief Financial Officer Sep 17 '24 Option Exercise 79.63 1,486 118,328 25,885 Sep 19 05:50 PM Korenberg Matthew E President & COO Sep 16 '24 Option Exercise 58.49 5,774 337,696 54,008 Sep 18 07:55 PM Espinoza Octavio Chief Financial Officer Aug 28 '24 Option Exercise 66.52 753 50,086 24,399 Aug 30 09:00 PM Reardon Andrew CLO & Secretary Aug 28 '24 Option Exercise 52.27 1,500 78,405 24,034 Aug 30 08:56 PM Reardon Andrew CLO & Secretary Aug 28 '24 Sale 106.39 1,500 159,591 22,534 Aug 30 08:56 PM Reardon Andrew Officer Aug 28 '24 Proposed Sale 106.39 1,500 159,590 Aug 28 04:39 PM Korenberg Matthew E President & COO Aug 26 '24 Sale 105.61 11,389 1,202,831 49,510 Aug 26 08:15 PM Korenberg Matthew E President & COO Aug 23 '24 Sale 104.80 6,312 661,479 60,899 Aug 26 08:15 PM Korenberg Matthew E President & COO Aug 22 '24 Sale 105.54 1,157 122,110 67,211 Aug 26 08:15 PM Korenberg Matthew E Officer Aug 22 '24 Proposed Sale 105.03 18,858 1,980,567 Aug 22 06:05 PM Korenberg Matthew E President & COO Aug 09 '24 Sale 98.50 18,245 1,797,132 68,368 Aug 13 05:21 PM Davis Todd C Chief Executive Officer Aug 08 '24 Buy 97.39 2,500 243,480 123,010 Aug 09 05:52 PM Korenberg Matthew E Officer Aug 09 '24 Proposed Sale 98.50 18,245 1,797,132 Aug 09 05:16 PM Gray Nancy Ryan Director May 09 '24 Sale 83.20 934 77,713 5,633 May 17 08:00 PM Espinoza Octavio Chief Financial Officer May 17 '24 Option Exercise 55.71 6,917 385,346 28,535 May 17 07:59 PM Espinoza Octavio Chief Financial Officer May 15 '24 Sale 86.01 5,873 505,148 23,882 May 17 07:59 PM Espinoza Octavio Chief Financial Officer May 17 '24 Sale 86.66 5,156 446,844 23,379 May 17 07:59 PM Espinoza Octavio Chief Financial Officer May 16 '24 Sale 86.00 2,264 194,712 21,618 May 17 07:59 PM Korenberg Matthew E President & Chief Operating May 14 '24 Sale 85.10 14,158 1,204,912 86,263 May 15 07:34 PM Korenberg Matthew E President & Chief Operating May 13 '24 Sale 84.54 3,440 290,828 100,421 May 15 07:34 PM Reardon Andrew Chief Legal Officer & May 09 '24 Option Exercise 52.27 10,000 522,700 32,205 May 13 05:32 PM Reardon Andrew Chief Legal Officer & May 09 '24 Sale 83.04 10,000 830,449 22,205 May 13 05:32 PM Aryeh Jason Director Apr 30 '24 Option Exercise 52.30 2,406 125,834 76,828 May 02 06:07 PM KOZARICH JOHN W Director Apr 24 '24 Option Exercise 39.35 2,893 113,840 42,523 Apr 26 06:35 PM Davis Todd C Chief Executive Officer Mar 25 '24 Option Exercise 57.39 16,015 919,147 120,160 Mar 27 05:47 PM Sabba Stephen L Director Mar 05 '24 Option Exercise 0.00 2,893 0 30,819 Mar 07 01:27 PM Sabba Stephen L Director Mar 05 '24 Sale 74.30 1,893 140,650 28,926 Mar 07 01:27 PM Aryeh Jason Director Mar 05 '24 Option Exercise 39.35 2,893 113,840 74,422 Mar 06 05:28 PM Espinoza Octavio Chief Financial Officer Feb 28 '24 Option Exercise 56.62 1,264 71,564 29,895 Feb 29 06:50 PM Espinoza Octavio Chief Financial Officer Feb 28 '24 Sale 88.46 140 12,384 29,755 Feb 29 06:50 PM Davis Todd C CHIEF EXECUTIVE OFFICER Sep 22 '23 Buy 59.38 4,000 237,529 73,090 Sep 25 04:44 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
